Scholarlink

Objectives <p>To evaluate the utility of fibroblast activation protein (FAP) imaging using [¹⁸F]FAPI PET/CT for assessing disease activity and monitoring treatment response in rheumatoid arthritis (RA).</p> Materials and methods <p>A prospective, single-center study was conducted with 42 RA patients and 8 healthy controls. Participants underwent clinical assessment and [¹⁸F]FAPI PET/CT imaging. Semiquantitative parameters, including standardized uptake value maximum (SUV<sub>max</sub>), lesion-to-muscle ratio (LMR), [¹⁸F]FAPI–avid lesion volume (FLV), and total lesion FAP expression (TLF), were analyzed. Disease activity was stratified by the disease activity score-28 using C-reactive protein (DAS28-CRP) into three groups (low, moderate, and high). Correlations between PET/CT parameters and disease acitivity were examined, and follow-up imaging was performed in ten patients to assess treatment response.</p> Results <p>[¹⁸F]FAPI PET/CT identified 201 RA-affected joints with significantly higher SUV<sub>max</sub> in positive joints compared to controls (median 3.6 vs 2.4; <i>p</i> &lt; 0.01). High disease activity was associated with increased SUV<sub>max</sub> (median 5.6 vs 3.3 vs 2.8; <i>p</i> &lt; 0.05), TBR (median 8.4 vs 3.0 vs 3.6; <i>p</i> &lt; 0.05), FLV (162.2 vs 11.5 vs 9.8; <i>p</i> &lt; 0.01), and TLF (569.1 vs 27.3 vs 22.7; <i>p</i> &lt; 0.01). Positive correlations were observed between DAS28-CRP and both FLV (<i>r</i> = 0.50, <i>p</i> &lt; 0.01) and TLF (<i>r</i> = 0.51, <i>p</i> &lt; 0.01). Follow-up imaging revealed significant associations between changes in disease activity and FAP burden.</p> Conclusion <p>[¹⁸F]FAPI PET/CT is a promising tool for non-invasive assessment of RA disease activity. It provides quantitative insights into fibroblast activation, offering potential to enhance disease management and therapeutic planning.</p> Key Points <p><Emphasis Type="BoldItalic">Question</Emphasis> <i>What is the potential of fibroblast activation imaging using [</i><sup><i>18</i></sup><i>F]FAPI PET/CT for assessing RA disease activity and monitoring treatment response</i>?</p> <p><Emphasis Type="BoldItalic">Findings</Emphasis> <sup><i>18</i></sup><i>F]FAPI PET/CT effectively identifies joint involvement and quantifies fibroblast activation, correlating closely with clinical disease activity in RA</i>.</p> <p><Emphasis Type="BoldItalic">Clinical relevance [</Emphasis><sup><i>18</i></sup><i>F]FAPI PET/CT provides a non-invasive, comprehensive assessment of RA activity, and possible cutoff values for identifying high disease activity</i>.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fibroblast activation imaging in rheumatoid arthritis: evaluating disease activity and treatment response using [18F]FAPI PET/CT

  • 期刊论文

  • 发表日期：

    2025年4月27日

查看全文
  • Xingyu Mu,
  • Fangyue Zhang,
  • Meng Li,
  • Lu Lu,
  • Biyun Mo,
  • Baozhen Li,
  • Min Yang,
  • Wei Fu

摘要

Objectives

To evaluate the utility of fibroblast activation protein (FAP) imaging using [¹⁸F]FAPI PET/CT for assessing disease activity and monitoring treatment response in rheumatoid arthritis (RA).

Materials and methods

A prospective, single-center study was conducted with 42 RA patients and 8 healthy controls. Participants underwent clinical assessment and [¹⁸F]FAPI PET/CT imaging. Semiquantitative parameters, including standardized uptake value maximum (SUVmax), lesion-to-muscle ratio (LMR), [¹⁸F]FAPI–avid lesion volume (FLV), and total lesion FAP expression (TLF), were analyzed. Disease activity was stratified by the disease activity score-28 using C-reactive protein (DAS28-CRP) into three groups (low, moderate, and high). Correlations between PET/CT parameters and disease acitivity were examined, and follow-up imaging was performed in ten patients to assess treatment response.

Results

[¹⁸F]FAPI PET/CT identified 201 RA-affected joints with significantly higher SUVmax in positive joints compared to controls (median 3.6 vs 2.4; p < 0.01). High disease activity was associated with increased SUVmax (median 5.6 vs 3.3 vs 2.8; p < 0.05), TBR (median 8.4 vs 3.0 vs 3.6; p < 0.05), FLV (162.2 vs 11.5 vs 9.8; p < 0.01), and TLF (569.1 vs 27.3 vs 22.7; p < 0.01). Positive correlations were observed between DAS28-CRP and both FLV (r = 0.50, p < 0.01) and TLF (r = 0.51, p < 0.01). Follow-up imaging revealed significant associations between changes in disease activity and FAP burden.

Conclusion

[¹⁸F]FAPI PET/CT is a promising tool for non-invasive assessment of RA disease activity. It provides quantitative insights into fibroblast activation, offering potential to enhance disease management and therapeutic planning.

Key Points

Question What is the potential of fibroblast activation imaging using [18F]FAPI PET/CT for assessing RA disease activity and monitoring treatment response?

Findings 18F]FAPI PET/CT effectively identifies joint involvement and quantifies fibroblast activation, correlating closely with clinical disease activity in RA.

Clinical relevance [18F]FAPI PET/CT provides a non-invasive, comprehensive assessment of RA activity, and possible cutoff values for identifying high disease activity.

Graphical Abstract